AzTrials
AzTrials

Abdominal Aortic Aneurysm Without RuptureAAA multiphaseNCT04150653

Non-invasive Aortic Aneurysm Tissue Characterization Using Wall Viscoelasticity

An observational study of Abdominal Aortic Aneurysm Without Rupture, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Abdominal aortic aneurysm (AAA) is an abnormal dilatation of the aorta in the abdomen due to a wall weakening caused by atherosclerosis. While indications for a rupture intervention are based on AAA maximal diameter (MaxD) (5 cm), 23% of ruptured AAAs are less than 5 cm and in large AAAs, rupture rate could be lower… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
Type of treatment
Medical device
How many people
30 participants
Where
1 siteCanada
Study dates
1 Sep 2020to 31 Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The target population is adults with AAA scheduled for elective repair. For the purpose of this study, we will recruit AAA patients seen at the CHUM and Glen campus McGill University.

Who may be able to join

  • Patient with a documented AAA (CT-scan or ultrasound less than 6 months before enrollment) with a maximum diameter (max D) between 4.5 cm and 7 cm.

Who cannot join

  • Ruptured, symptomatic or not atheromatous aneurysm;
  • Renal failure (renal serum clearance <50 mL/min);
  • Previous intervention on AAA (general or endovascular surgery);
  • BMI >35;
  • Atrial fibrillation.

Trial locations and contacts

1 site in 1 country.

Canada1 site, 1 recruiting
  • Centre Hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 0C1

    Samuel Kadoury, PhD, 514-890-8000 ext. 31394, samuel.kadoury@polymtl.ca

    Jennifer Satterthwaite, MSc, 514-890-8000 ext. 23483, jennifer.satterthwaite.chum@ssss.gouv.qc.ca

    Recruiting

Other trials in Canada

About this study

Abdominal aortic aneurysm (AAA) is an abnormal dilatation of the aorta in the abdomen due to a wall weakening caused by atherosclerosis. While indications for a rupture intervention are based on AAA maximal diameter (MaxD) (5 cm), 23% of ruptured AAAs are less than 5 cm and in large AAAs, rupture rate could be lower than expected. We propose to expand and validate our vascular ultrasound elastography software to 3D. Strain maps generated from radiofrequency (RF) data acquired from 30 AAA patients with a matrix-array 3D probe will be registered to conventional CT (phase 1) and validated to a biomechanical for characterization of AAA wall, assessing vulnerability and influence of surrounding tissues (phase 2). At the end of the project, we will have analyzed 3D strain maps to improve patient selection before surgery.

Read the detailed description

BACKGROUND - Abdominal aortic aneurysm (AAA) rupture is the 13th cause of death in North America. The indications for a procedure to prevent rupture are based on AAA maximal diameter. However, it is a dichotomic criteria leading to under or over estimation of rupture risk. Biomechanics based criteria have been investigated using Finite Elements Analysis (FEA). The limitation of FEA is the absence of patient specific biomechanical information. Our team have previously developped a technique to map in-vivo the strain of AAAs, named non-invasive vascular elastography by ultrasound (NIVE). However, it relies on 2D ultrasound series, whereas new matrix- array probes allow a 3D mapping of the strain at a lower temporal resolution. We propose to create a 3D mapping of AAA strain with 3D ultrasound and register the strain mapping on a single phase CT.

In the project, we plan to acquire multi-modal imaging from 30 AAA patients scheduled for an elective repair will be recruited. A 3D NIVE examination and multiphase CT will be performed on each patient within less than one month of their surgery. A portion of the AAA wall will be harvested during surgery to correlate strains with tensile tests and histology. Following the implementation of NIVE processing and 3D registration, the NIVE and multiphase CT strain values will be calculated and if necessary controlled for the measurement of blood pressure, AAA maximal diameter, calcium load, gender and age. A FEA model developed at U of Calgary will be personalized using the calculation of in-vivo strains. Comparison of strain measurement between NIVE and multiphase CT, correlation of strain measurements and personalized FEA with AAA growth will constitute secondary endpoints. Following the complete validation of this personalized model, we anticipate this will provide predictive biomarkers for AAA vulnerability.

OBJECTIVES - Primary objectives: 1. Acquire a multimodal image dataset (multiphase CT, 3D US) from 30 AAA patients undergoing repair surgery (phase 1); 2. Optimize and validate in vitro the NIVE acquisition protocol and the image registration algorithm between NIVE and one phase of the multiphase CT (phase 1); 3. Compare the principal strain distribution assessed with 3D NIVE registered on conventional CT and those imaged with multiphase CT acquisition (phase 1); 4. Validate both approaches with histology and tensile test on AAA samples (phase 2).

Main hypothesis: Strain maps with 3D NIVE registered on single phase CT provide an accurate in-vivo estimation of AAA wall strength and yield similar accuracy to strain from multiphase CT to assess AAA vulnerability.

METHODOLOGY Phase 1 only will be done for the moment - Design: We plan a prospective study involving 30 AAA patients scheduled for elective open repair. For the phase 1 of the study, we will perform in all patients a NIVE examination and multiphase CT within less than one month of their surgery. For the phase 2 of the study, patient undergoing open surgery will be recruited. A portion of the AAA wall will be harvested during surgery (outside of scope of the pilot study) in order to perform biaxial tensile tests and histology examination. Patients will be recruited at the Centre hospitalier de l'Université de Montréal (CHUM) and Glen campus McGill University.

Data analysis: Spearman correlation, accuracy evaluated by mean error and standard deviation, intraclass correlation coefficient, Bland-Altmann analysis, mixed linear model to evaluate the influence of sex, MaxD, pulse pressure, calcification score on strain (NIVE, multiphase CT) measurements.

RATIONALE AND IMPACT - Ruptured AAA (rAAA) is a life-threatening situation which is the 13th mortality cause in USA. Endovascular aneurysm repair (EVAR) is often preferred for rAAA for its lower morbidity and mortality as compared with OR (1.6 versus 5%). But these data show the maximal diameter/rupture relationship to be nonlinear and inaccurate to predict rupture. New imaging biomarkers to predict AAA growth and rupture are therefore needed. There is also a need to personalize the tissue modeling with in vivo assessment of AAA wall strain to improve prediction of AAA rupture or growth. At the end of the study, we anticipate to have complete validation of this non-invasive assessment of AAA wall vulnerability using US-CT fusion,that will constitute the basis of a personalized assessment of AAA vulnerability. The strain mapping can be used to improve patient selection or be incorporated in a FEA model. Our personalized predictive model will also be useful for EVAR procedure simulation, planning and guidance.

Being tested
Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
Keywords
Abdominal aortic aneurysm rupture prevention, Non-invasive vascular elastography by ultrasound, 3D mapping of AAA strain, Vascular vulnerability assessment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)Device

    Also called Multiphase scan CT, Non-invasive vascular ultrasound elastography by ultrasound (NIVE)

    Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)

Study groups in NCT04150653
Study groupRoleWhat they receive
AAA patientsAll patients enrolled in phase 1 will undergo: * Multiphase scan CT * Non-invasive vascular ultrasound elastography by ultrasound (NIVE)
Receives: Device: Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. AAA strain measurement

    Measure of AAA strain values using imaging exams

    Measured: Within less than one month of their surgery

Secondary outcomes (2)
  1. AAA strain measurement determined by NIVE

    Measure of AAA strain using non-invasive vascular elastography by ultrasound (NIVE)

    Measured: Within less than one month of their surgery

  2. AAA strain measurement determined by multiphase CT

    Measure of AAA strain using multiphase CT scan

    Measured: Within less than one month of their surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2019
  2. Study start1 Sep 2020
  3. Primary completion31 Dec 2023 (estimated)
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04150653
Sponsor's protocol ID
19.261
Acronym
AAA multiphase
Status last verified
Mar 2023
First submitted
1 Nov 2019
Last updated
10 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Abdominal Aortic Aneurysm Without Rupture, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Samuel Kadoury, PhD (514-890-8000 ext. 31394, samuel.kadoury@polymtl.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

AAA strain measurement (time frame: Within less than one month of their surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in